Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

May 20, 2022

Study Completion Date

June 22, 2022

Conditions
COVID19
Interventions
DRUG

nangibotide

nangibotide 1.0 mg/kg/h

DRUG

placebo

matching placebo

Trial Locations (17)

3600

Ziekenhuis Oost-Limburg, Genk

21079

CHU Dijon - Bourgogne - Hôpital François Mitterrand, Dijon

34295

Hôpital Saint Eloi CHU Montpellier, Montpellier

37044

CHRU - Hôpital Bretonneau, Tours

44093

Hôpital Dieu - CHU Nanates, Nantes

49933

CHU Angers, Angers

54000

Réanimation Médicale, Hôpital Central, Nancy

62400

Centre Hospitalier Germont et Gauthier, Béthune

67091

Hôpital Civil - Nouvel Hôpital civil, Strasbourg

72037

Centre hospitalier le Manas, Le Mans

75014

Hôpital Cochin, Paris

77000

Centre hospitalier de Melun, Melun

87042

Centre Hospitalier Universitaire Dupuytren, Limoges

90400

Hôpital Franch-Comté Site Trevenans, Trévenans

95107

Centre hospitalier Victor Dupouy, Argenteuil

B-1200

Clinique universitaire Saint-Luc, Brussels

85 925

CHD Site la Roche sur Yon, les Oudairies, La Roche-sur-Yon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Inotrem

INDUSTRY